PURPOSE: To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities. PATIENTS AND METHODS: A phase II trial was conducted by the Gynecologic Oncology Group. Patients must have had cancer that had progressed on platinum-based primary chemotherapy or recurred within 6 months. Pemetrexed at a dose of 900 mg/m(2) was to be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay and adjustment was permitted for toxicity. Treatment was continued until disease progression or unacceptable adverse effects. RESULTS: From July 6, 2004, to August 23, 2006, 51 patients were entered. A total of 259 cycles (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients receiving six or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in 15% of patients. No treatment-related deaths were reported. One patient (2%) had a complete and nine patients (19%) had partial responses, with a median duration response of 8.4 months. Seventeen patients (35%) had stable disease for a median of 4.1 months. Eighteen patients (38%) had increasing disease. Three patients (6%) were not assessable. Median progression-free survival was 2.9 months, and overall survival was 11.4 months. CONCLUSION: Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation.
PURPOSE: To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities. PATIENTS AND METHODS: A phase II trial was conducted by the Gynecologic Oncology Group. Patients must have had cancer that had progressed on platinum-based primary chemotherapy or recurred within 6 months. Pemetrexed at a dose of 900 mg/m(2) was to be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay and adjustment was permitted for toxicity. Treatment was continued until disease progression or unacceptable adverse effects. RESULTS: From July 6, 2004, to August 23, 2006, 51 patients were entered. A total of 259 cycles (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients receiving six or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in 15% of patients. No treatment-related deaths were reported. One patient (2%) had a complete and nine patients (19%) had partial responses, with a median duration response of 8.4 months. Seventeen patients (35%) had stable disease for a median of 4.1 months. Eighteen patients (38%) had increasing disease. Three patients (6%) were not assessable. Median progression-free survival was 2.9 months, and overall survival was 11.4 months. CONCLUSION:Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation.
Authors: Tanguy Y Seiwert; Philip P Connell; Ann M Mauer; Philip C Hoffman; Christopher M George; Livia Szeto; Ravi Salgia; Katherine E Posther; Binh Nguyen; Daniel J Haraf; Everett E Vokes Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Cheryl A Brewer; John A Blessing; Robert A Nagourney; Mark Morgan; Parviz Hanjani Journal: Gynecol Oncol Date: 2006-04-27 Impact factor: 5.482
Authors: R Thödtmann; H Depenbrock; H Dumez; J Blatter; R D Johnson; A van Oosterom; A R Hanauske Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: P M Fracasso; M F Brady; D H Moore; J L Walker; P G Rose; L Letvak; T M Grogan; W P McGuire Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: Mark A Socinski; Charles Weissman; Lowell L Hart; J Thaddeus Beck; Janak K Choksi; John P Hanson; Diane Prager; Matthew J Monberg; Zhishen Ye; Coleman K Obasaju Journal: J Clin Oncol Date: 2006-10-20 Impact factor: 44.544
Authors: Chris H Takimoto; Lisa A Hammond-Thelin; Jane E Latz; Leonardo Forero; Muralidhar Beeram; Bahram Forouzesh; Johann de Bono; Anthony W Tolcher; Amita Patnaik; Pamela Monroe; Leslie Wood; Karen B Schneck; Romnee Clark; Eric K Rowinsky Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Keith C Bible; Prema P Peethambaram; Ann L Oberg; William Maples; David L Groteluschen; Matthew Boente; Jill K Burton; Leigh C Gomez Dahl; Jennifer D Tibodeau; Crescent R Isham; Jacie L Maguire; Viji Shridhar; Andrea K Kukla; Kalli J Voll; Mathew J Mauer; Alexander D Colevas; John Wright; L Austin Doyle; Charles Erlichman Journal: Gynecol Oncol Date: 2012-06-01 Impact factor: 5.482
Authors: Xiaoyu Song; Jiayi Ji; Kevin J Gleason; Fan Yang; John A Martignetti; Lin S Chen; Pei Wang Journal: Mol Cell Proteomics Date: 2019-06-21 Impact factor: 5.911
Authors: Robert L Coleman; William E Brady; D Scott McMeekin; Peter G Rose; John T Soper; Samuel S Lentz; James S Hoffman; Mark S Shahin Journal: Gynecol Oncol Date: 2011-04-15 Impact factor: 5.482
Authors: Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio Journal: Cancer Res Date: 2012-05-22 Impact factor: 12.701
Authors: Donald A Richards; David Loesch; Svetislava J Vukelja; Hillary Wu; William J Hyman; Jeffery Nieves; Yunfei Wang; Simin Hu; Oluwatoyin O Shonukan; Datchen F Tai Journal: Invest New Drugs Date: 2010-03-30 Impact factor: 3.850
Authors: Setsuko K Chambers; H-H Sherry Chow; Mike F Janicek; Janiel M Cragun; Kenneth D Hatch; Haiyan Cui; Cynthia Laughren; Mary C Clouser; Janice L Cohen; Heather M Wright; Nisreen Abu Shahin; David S Alberts Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Andrea R Hagemann; Akiva P Novetsky; Israel Zighelboim; Feng Gao; L Stewart Massad; Premal H Thaker; Matthew A Powell; David G Mutch; Jason D Wright Journal: Gynecol Oncol Date: 2013-10-04 Impact factor: 5.482